EHA Library - The official digital education library of European Hematology Association (EHA)

DETERMINANTS OF IN VIVO EXPANSION OF CD19 SPECIFIC CAR T-CELLS IN LARGE B-CELL LYMPHOMA: SINGLE CENTER IMMUNMONITORING RESULTS
Author(s): ,
Viktoria Blumenberg
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany
,
Galina Busch
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
,
Stephan Baumann
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
,
Daniel Nixdorf
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
,
Gerulf Hänel
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
,
Lisa Fröhlich
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany
,
Christian Schmidt
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany
,
Benjamin Tast
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
,
Michael von Bergwelt
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany
,
Veit Bücklein
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany
Marion Subklewe
Affiliations:
Department of Medicine III,University Hospital, LMU Munich,Munich,Germany;Laboratory for Translational Cancer Immunology,Gene Center of the LMU Munich,Munich,Germany;German Cancer Consortium (DKTK),German Cancer Research Center (DKFZ),Heidelberg,Germany
EHA Library. Blumenberg V. 06/09/21; 325485; EP725
Viktoria Blumenberg
Viktoria Blumenberg
Contributions
Abstract
Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP725

Type: E-Poster Presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research

Background

Pivotal trials of Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for the treatment of relapsed and refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) demonstrated complete responses in 40%>58% of the patients with accompanied grade ≥3 adverse events in approximately 30% of the patients. Recently, others could associate high tumor volumne and low CAR T-cell expansion in vivo with poor treatment outcome. We hypothesize, that expansion of CAR T-cells and T cells in vivo depend on the composition and differentiation status of (CAR) T-cell subsets and that differential expansion of (CAR) T cell subsets determines response rate.

Aims
We performed a retrospective, single-center study in which we characterized potential determinants of CAR T-cell and T-cell expansion[MS1]  and their association with treatment response at time of transfusion and 28 days thereafter: i) the distribution of CD4+ and CD8+ (CAR) T-cells subsets ii) the memory phenotype and immune checkpoint expression of (CAR) T-cells.

Methods
Patients with r/r DLBCL were treated with the CD19 specific CAR T-cell products Axi-cel or Tisa-cel at the LMU. Peripheral blood from 38 patients was collected before, during and after CAR T transfusion. Multi-parameter flow cytometry was done to detect CAR T-cells and assess marker for T-cell differentiation (CD3, CD4, CD8, CD45RA, CCR7) and immune checkpoints (PD-1, TIM-3, LAG-3). CAR T-cells were quantified based on a two step-staining approach with a biotinylated recombinant CD19 protein. Efficacy was evaluated through PET-CT scan three months and by CT scan six months after CAR T-cell transfusion and patients were categorized in Responder (complete remission) and Non-Responder (partial remission, stable or progressive disease).

Results
CAR T-cell expansion peaked between day 7 and 14 in the peripheral blood with a significantly higher expansion of CD8+ CAR T-cells compared to CD4+ CAR T-cells between day 4 and 28 (p=0.004-0.007). CAR T-cells were detectable in most patients until day 105 (sensitivity 1:1000). Responder (R) displayed a higher absolute number of CD8+ CAR T-cells over time after transfusion compared to Non-Responder (NR, p=0.02). CAR T-cells in R showed a higher frequency of an effector (p=0.004) and lower frequency of a central memory phenotype (p=0.002) compared to NR 28 days after CAR T-cell transfusion. Furthermore, assessment of immune checkpoints over time revealed a lower expression of PD-1 (p<0.0001), TIM-3 (p<0.0001), LAG-3 (p=0.001) on CAR T-cells in R compared to NR.

Conclusion
We have successfully established an Immunmonitoring platform for the assessment of CAR T-cell expansion and their immune phenotypes in vivo through flow cytometry. We observed relationships of CAR T-cell kinetics, memory subsets and immune checkpoint expression with efficacy. These findings might bear the potential to monitor treatment responses and prevent disease relapse together with other clinical variables.

Keyword(s): CAR-T, Diffuse large B cell lymphoma, Flow cytometry, T cell expansion

Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP725

Type: E-Poster Presentation

Session title: Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research

Background

Pivotal trials of Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for the treatment of relapsed and refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) demonstrated complete responses in 40%>58% of the patients with accompanied grade ≥3 adverse events in approximately 30% of the patients. Recently, others could associate high tumor volumne and low CAR T-cell expansion in vivo with poor treatment outcome. We hypothesize, that expansion of CAR T-cells and T cells in vivo depend on the composition and differentiation status of (CAR) T-cell subsets and that differential expansion of (CAR) T cell subsets determines response rate.

Aims
We performed a retrospective, single-center study in which we characterized potential determinants of CAR T-cell and T-cell expansion[MS1]  and their association with treatment response at time of transfusion and 28 days thereafter: i) the distribution of CD4+ and CD8+ (CAR) T-cells subsets ii) the memory phenotype and immune checkpoint expression of (CAR) T-cells.

Methods
Patients with r/r DLBCL were treated with the CD19 specific CAR T-cell products Axi-cel or Tisa-cel at the LMU. Peripheral blood from 38 patients was collected before, during and after CAR T transfusion. Multi-parameter flow cytometry was done to detect CAR T-cells and assess marker for T-cell differentiation (CD3, CD4, CD8, CD45RA, CCR7) and immune checkpoints (PD-1, TIM-3, LAG-3). CAR T-cells were quantified based on a two step-staining approach with a biotinylated recombinant CD19 protein. Efficacy was evaluated through PET-CT scan three months and by CT scan six months after CAR T-cell transfusion and patients were categorized in Responder (complete remission) and Non-Responder (partial remission, stable or progressive disease).

Results
CAR T-cell expansion peaked between day 7 and 14 in the peripheral blood with a significantly higher expansion of CD8+ CAR T-cells compared to CD4+ CAR T-cells between day 4 and 28 (p=0.004-0.007). CAR T-cells were detectable in most patients until day 105 (sensitivity 1:1000). Responder (R) displayed a higher absolute number of CD8+ CAR T-cells over time after transfusion compared to Non-Responder (NR, p=0.02). CAR T-cells in R showed a higher frequency of an effector (p=0.004) and lower frequency of a central memory phenotype (p=0.002) compared to NR 28 days after CAR T-cell transfusion. Furthermore, assessment of immune checkpoints over time revealed a lower expression of PD-1 (p<0.0001), TIM-3 (p<0.0001), LAG-3 (p=0.001) on CAR T-cells in R compared to NR.

Conclusion
We have successfully established an Immunmonitoring platform for the assessment of CAR T-cell expansion and their immune phenotypes in vivo through flow cytometry. We observed relationships of CAR T-cell kinetics, memory subsets and immune checkpoint expression with efficacy. These findings might bear the potential to monitor treatment responses and prevent disease relapse together with other clinical variables.

Keyword(s): CAR-T, Diffuse large B cell lymphoma, Flow cytometry, T cell expansion

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies